Quarterly report pursuant to Section 13 or 15(d)

Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details)

v3.19.3
Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
Jul. 15, 2019
Sep. 30, 2019
Dec. 31, 2018
Business Acquisition [Line Items]      
Total acquired identifiable intangible assets $ 7,300,000 $ 7,600,000  
Goodwill 8,300,000 $ 8,273,000
BioPharma Acquisition [Member]      
Business Acquisition [Line Items]      
Cash 13,829,000    
Subordinated note payable 6,822,000    
Total consideration 20,651,000    
Accounts receivable 3,731,000    
Accrued revenue 289,000    
Lab supplies 877,000    
Prepaid expenses 266,000    
Property and equipment 6,412,000    
Operating lease assets 2,187,000    
Total acquired identifiable intangible assets 7,300,000    
Goodwill 8,273,000    
Total assets acquired 29,335,000    
Accounts payable (4,535,000)    
Accrued liabilities (435,000)    
Deferred revenue (1,076,000)    
Operating lease liabilities (2,187,000)    
Finance lease liabilities (451,000)    
Total liabilities assumed (8,684,000)    
Net assets acquired 20,651,000    
BioPharma Acquisition [Member] | Trademarks and Trade Name [Member]      
Business Acquisition [Line Items]      
Total acquired identifiable intangible assets 1,600,000    
BioPharma Acquisition [Member] | Customer Relationships [Member]      
Business Acquisition [Line Items]      
Total acquired identifiable intangible assets $ 5,700,000